Stockreport

Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to buil [Read more]